CN118871439A - 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途 - Google Patents

外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途 Download PDF

Info

Publication number
CN118871439A
CN118871439A CN202380026751.8A CN202380026751A CN118871439A CN 118871439 A CN118871439 A CN 118871439A CN 202380026751 A CN202380026751 A CN 202380026751A CN 118871439 A CN118871439 A CN 118871439A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380026751.8A
Other languages
English (en)
Chinese (zh)
Inventor
程鑫
刘颖涛
秦泺恒
任峰
余华星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingsi Intelligent Technology Intellectual Property Co ltd
Original Assignee
Yingsi Intelligent Technology Intellectual Property Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yingsi Intelligent Technology Intellectual Property Co ltd filed Critical Yingsi Intelligent Technology Intellectual Property Co ltd
Publication of CN118871439A publication Critical patent/CN118871439A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380026751.8A 2022-01-28 2023-01-28 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途 Pending CN118871439A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/074739 2022-01-28
CN2022074739 2022-01-28
CNPCT/CN2022/140318 2022-12-20
CN2022140318 2022-12-20
PCT/CN2023/073579 WO2023143520A1 (en) 2022-01-28 2023-01-28 Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN118871439A true CN118871439A (zh) 2024-10-29

Family

ID=87470622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380026751.8A Pending CN118871439A (zh) 2022-01-28 2023-01-28 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途

Country Status (12)

Country Link
US (1) US20250101019A1 (https=)
EP (1) EP4469456A4 (https=)
JP (1) JP2025502943A (https=)
KR (1) KR20240142481A (https=)
CN (1) CN118871439A (https=)
AR (1) AR128383A1 (https=)
AU (1) AU2023213905A1 (https=)
CA (1) CA3247162A1 (https=)
IL (1) IL313821A (https=)
MX (1) MX2024009216A (https=)
TW (1) TW202340190A (https=)
WO (1) WO2023143520A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074128A1 (en) * 2022-10-08 2024-04-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
CN121793967A (zh) * 2023-07-06 2026-04-03 英矽智能科技知识产权有限公司 外切核苷酸焦磷酸酶/磷酸二酯酶1 (enpp1)抑制剂组合及其用途
CN121969621A (zh) * 2023-08-02 2026-05-01 英矽智能科技知识产权有限公司 外核苷酸焦磷酸酶-磷酸二酯酶1 (enpp1)抑制剂的结晶形式及其用途
WO2025026377A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98674B (pt) * 1990-08-15 1999-01-29 British Bio Technology Processo para a preparacao de compostos que sao antagonistas do factor de activacao de plaquetas por exemplo derivados de imidazole e de seus intermedriarios
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
PE20081354A1 (es) * 2006-11-30 2008-11-14 Genentech Inc Compuestos de azaindolilo como inhibidores de mek
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2019023635A1 (en) * 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
ES2960987T3 (es) * 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
KR20220068243A (ko) * 2019-09-23 2022-05-25 난징 젱시앙 파마슈티칼스 컴퍼니 리미티드 포스포디에스테라제 억제제 및 용도
MX2023008761A (es) * 2021-01-29 2023-08-22 Txinno Bioscience Inc Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo.

Also Published As

Publication number Publication date
IL313821A (en) 2024-08-01
JP2025502943A (ja) 2025-01-30
AU2023213905A1 (en) 2024-07-11
AR128383A1 (es) 2024-04-24
WO2023143520A1 (en) 2023-08-03
US20250101019A1 (en) 2025-03-27
EP4469456A1 (en) 2024-12-04
TW202340190A (zh) 2023-10-16
KR20240142481A (ko) 2024-09-30
EP4469456A4 (en) 2025-12-31
CA3247162A1 (en) 2023-08-03
MX2024009216A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
CN113024544B (zh) 一种含氰基并杂环化合物及其用途
CN118871439A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途
JP6898868B2 (ja) Ｈｐｋ１阻害剤およびそれを用いる方法
JP2024516997A (ja) Ｓｈｐ２阻害剤単独療法およびその使用
JP6431593B6 (ja) ピリジニルアミノピリミジン誘導体、その製造方法、および用途
JP7680619B2 (ja) Ｐａｒｐ１阻害薬及びその使用
CN118434722A (zh) 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN118221698A (zh) Kras g12d抑制剂
JP2026001129A (ja) Ｐａｒｐ１阻害薬及びその使用
JP2021512161A (ja) Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ−インダゾール誘導体およびその治療上の使用
CN118488838A (zh) 含脯氨酰羟化酶结构域的蛋白质(phd)抑制剂及其用途
WO2024074128A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
JP2025514382A (ja) Ｒｏｃｋ２の阻害剤
CN118829642A (zh) 二酰基甘油激酶(DGK)α抑制剂及其用途
CN118871438A (zh) 二酰基甘油激酶(DGK)α抑制剂及其用途
CN108601773B (zh) 作为pi3k/mtor抑制剂的稠合喹啉化合物
CN117043163A (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
HK40116343A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途
WO2025026377A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
EA052691B1 (ru) Ингибиторы эктонуклеотидпирофосфатазы-фосфодиэстеразы 1 (enpp1) и их применение
AU2010242394B2 (en) Purine derivative and antitumor agent using same
ZA200700240B (en) Inhibitors of VEGF receptor and HGF receptor signaling

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116343

Country of ref document: HK